|
Herceptin (trastuzumab). Importance of cardiac monitoring to reduce the frequency and severity of left ventricular dysfunction and congestive heart failure during trastuzumab therapy
|
|
Mirabegron (Betmiga) - new recommendations about the risk of increase in blood pressure
|
|
Important safety update of prescribing information for Xeloda® (capecitabine)
|
|
Bioparox (fusafungine) aerosol will no longer be available on the market
|
|
CellCept® (mycophenolate mofetil): teratogenic risk prevention
|
|
Bioparox (fusafungine) spray: new contra-indications and recommendations to minimize the risk of serious allergic reactions
|
